SAN DIEGO, May 29, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB:ONCS), which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that Punit Dhillon, President and CEO at OncoSec, will be presenting at BioFinance 2012 in Toronto, Canada, on Wednesday, May 30, 2012.
St. Andrew's Club & Conference Centre
150 King Street West
Toronto, Canada M5H 1J9
May 29-30, 2012
Wednesday, May 30, 2012
BioFinance 2012 is the Canadian forum for some of the most innovative minds in the life sciences industry today, with attendance ranging from company CEO's, CFO's and senior executives, institutional and private equity investors from the US and Canada, industry analysts, corporate finance executives and experts from pharmaceutical, agriculture biotech communities in Canada, the US and Europe. Program presentations range from publicly traded and major private companies to early-stage seed opportunities. Company presentations will span a range of industries including biologics, medical devices, drug delivery, vaccines, diagnostics, bio-energy, green technologies, bio materials, industrial biotech, and research services. These companies will also highlight their solid potential, strong management and funding requirements in the $2-$100 million range.
To arrange a meeting with management please contact Adam Holdsworth,
The Investor Relations Group 212-825-3210 firstname.lastname@example.org
About OncoSec Medical Inc.
OncoSec Medical Incorporated is a biopharmaceutical company developing advanced-stage OMS ElectroOncology therapies to treat solid tumors and metastatic disease. OMS ElectroOncology therapies address an unmet medical need and represent a potential solution for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from traditional cancer treatments. OncoSec's core technology is based upon its proprietary use of an electroporation platform, to dramatically enhance the delivery and uptake of a locally delivered DNA-based immuno-cytokine or a chemotherapeutic agent. Treatment of various solid cancers using these targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy targeting lethal skin cancers. More information is available at www.oncosec.com.
This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
SOURCE OncoSec Medical Incorporated